靶向间皮素的T细胞受体融合构建体细胞疗法治疗难治性实体瘤:1/2期试验中期结果
该1/2期试验中期结果报告了gavo-cel(一种靶向间皮素的T细胞受体融合构建体)在32例难治性间皮素表达实体瘤患者中的安全性和疗效。推荐的2期剂量为淋巴细胞清除后1×10^8细胞/m²。可评估的30例患者中,总缓解率为20%(其中13%为确认缓解),疾病控制率为77%,6个月总生存率为70%。
要点
- 推荐的2期剂量为淋巴细胞清除后1×10^8细胞/m²。
- 所有患者中3级及以上肺炎发生率为16%,推荐2期剂量组为0%。
- 可评估患者总缓解率20%(确认缓解13%),疾病控制率77%,6个月总生存率70%。
核心结论
- Gavo-cel在间皮素表达癌症患者中显示出令人鼓舞的抗肿瘤活性,但可能治疗窗较窄,需进一步研究。
研究设计与样本
- 正在进行的1/2期试验的1期结果,32例难治性间皮素表达实体瘤患者接受gavo-cel,其中单药治疗3例,淋巴细胞清除后治疗29例。
主要发现
- 观察到剂量限制性毒性包括3级肺炎和5级细支气管肺泡出血。
- 所有患者中3级及以上肺炎发生率为16%,推荐2期剂量组为0%。
- 所有患者中3级及以上细胞因子释放综合征发生率为25%,推荐2期剂量组为15%。
- 30例可评估患者中,总缓解率为20%(确认缓解率13%),疾病控制率为77%,6个月总生存率为70%。
关键数值与推荐
- 推荐的2期剂量为淋巴细胞清除后1×10^8细胞/m²。
临床怎么用
- 原文未据此给出推荐。
局限性
- Gavo-cel可能治疗窗较窄。
- Gavo-cel需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The T cell receptor fusion construct (TRuC) gavocabtagene autoleucel (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous T cell receptor (TCR) and engages the signaling capacity of the entire TCR upon mesothelin binding. Here we describe phase 1 results from an ongoing phase1/2 trial of gavo-cel in patients with treatment-refractory mesothelin-expressing solid tumors. The primary objectives were to evaluate safety and determine the recommended phase 2 dose (RP2D). Secondary objectives included efficacy. Thirty-two patients received gavo-cel at increasing doses either as a single agent (n = 3) or after lymphodepletion (LD, n = 29). Dose-limiting toxicities of grade 3 pneumonitis and grade 5 bronchioalveolar hemorrhage were noted. The RP2D was determined as 1 × 108 cells per m2 after LD. Grade 3 or higher pneumonitis was seen in 16% of all patients and in none at the RP2D; grade 3 or higher cytokine release syndrome occurred in 25% of all patients and in 15% at the RP2D. In 30 evaluable patients, the overall response rate and disease control rate were 20% (13% confirmed) and 77%, respectively, and the 6-month overall survival rate was 70%. Gavo-cel warrants further study in patients with mesothelin-expressing cancers given its encouraging anti-tumor activity, but it may have a narrow therapeutic window. ClinicalTrials.gov identifier: NCT03907852 .
引用
- Hassan R, Butler M, O'Cearbhaill RE, et al. Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results. Nat Med. 2023. PMID: 37501016. doi:10.1038/s41591-023-02452-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。